Correlation Between Sarepta Therapeutics and Protalix Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sarepta Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Sarepta Therapeutics and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Protalix Biotherapeutics.
Diversification Opportunities for Sarepta Therapeutics and Protalix Biotherapeutics
-0.19 | Correlation Coefficient |
Good diversification
The 3 months correlation between Sarepta and Protalix is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Protalix Biotherapeutics go up and down completely randomly.
Pair Corralation between Sarepta Therapeutics and Protalix Biotherapeutics
Given the investment horizon of 90 days Sarepta Therapeutics is expected to under-perform the Protalix Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sarepta Therapeutics is 1.64 times less risky than Protalix Biotherapeutics. The stock trades about -0.06 of its potential returns per unit of risk. The Protalix Biotherapeutics is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest 107.00 in Protalix Biotherapeutics on November 2, 2024 and sell it today you would earn a total of 131.00 from holding Protalix Biotherapeutics or generate 122.43% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Sarepta Therapeutics vs. Protalix Biotherapeutics
Performance |
| Timeline |
| Sarepta Therapeutics |
| Protalix Biotherapeutics |
Sarepta Therapeutics and Protalix Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Sarepta Therapeutics and Protalix Biotherapeutics
The main advantage of trading using opposite Sarepta Therapeutics and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.| Sarepta Therapeutics vs. Krystal Biotech | Sarepta Therapeutics vs. PTC Therapeutics | Sarepta Therapeutics vs. Iovance Biotherapeutics | Sarepta Therapeutics vs. Madrigal Pharmaceuticals |
| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |